The share price of Tandem Diabetes Care Inc. (NASDAQ:TNDM) fell to $34.92 per share on Monday from $35.67. While Tandem Diabetes Care Inc. has underperformed by -2.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TNDM fell by -47.76%, with highs and lows ranging from $70.81 to $23.60, whereas the simple moving average fell by -8.97% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
On May 05, 2023, BofA Securities Downgraded Tandem Diabetes Care Inc. (NASDAQ: TNDM) to Underperform.
Analysis of Tandem Diabetes Care Inc. (TNDM)
Further, the quarter-over-quarter decrease in sales is -3.70%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Tandem Diabetes Care Inc.’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -49.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.70, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and TNDM is recording an average volume of 1.34M. On a monthly basis, the volatility of the stock is set at 5.61%, whereas on a weekly basis, it is put at 5.98%, with a gain of 3.47% over the past seven days. Furthermore, long-term investors anticipate a median target price of $50.29, showing growth from the present price of $34.92, which can serve as yet another indication of whether TNDM is worth investing in or should be passed over.
How Do You Analyze Tandem Diabetes Care Inc. Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.10%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 104.88% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in TNDM shares?
The recent increase in stakes in TNDM appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in TNDM has increased by 48.73% in the first quarter. The company now owns 8,391,695 shares of the stock, with a value of $205.93 million, following the purchase of 2,749,424 additional shares during the last quarter. The Vanguard Group, Inc. made another increased to its shares in TNDM during the first quarter, upping its stake by 15.16%. During the last quarter, the company picked up 915,317 additional shares for a total stake of worth $170.61 million, bringing number of shares owned by the company to 6,952,467.
During the first quarter, Capital Research & Management Co added a 516,662 position in TNDM. Fidelity Management & Research Co sold an additional -1.49 million shares in the last quarter, decreasing its holdings by -19.08%, now holding 6.31 million shares worth $154.94 million. At the end of the first quarter, Champlain Investment Partners LLC increased its TNDM holdings by 6.66% and now holds 3.27 million TNDM shares valued at $80.32 million with the added 0.2 million shares during the period. TNDM shares are owned by institutional investors to the tune of 104.88% at present.
